(Q40172561)

18 September 2017

1 reference

title

Current status and perspectives in the treatment of non-Hodgkin's lymphomas (English)

1 reference

18 September 2017

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

9 October 2023

2

Cavalli F

1 reference

18 September 2017

H. P. Honegger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6368244

9 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6368244

9 October 2023

publication date

1 March 1984

1 reference

full work available at URL

18 September 2017

https://api.elsevier.com/content/article/PII:0277537984900749?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

https://api.elsevier.com/content/article/PII:0277537984900749?httpAccept=text/plain

9 October 2023

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

European Journal of Cancer & Clinical Oncology

9 October 2023

published in

1 reference

18 September 2017

volume

20

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

305-314

1 reference

Letter: Classification of non-Hodgkin's lymphomas.

18 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Cytological and functional criteria for the classification of malignant lymphomata

9 October 2023

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Lukes-Collins classification and its significance

9 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

U.S. National Cancer Institute working formulation of non-Hodgkin's lymphomas for clinical use

9 October 2023

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy

9 October 2023

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Morphologic types of diffuse large-cell lymphoma

9 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Estimation of differential in vitro sensitivity of non-hodgkin lymphomas to anticancer drugs

9 October 2023

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma.

9 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Correlations between immunologic markers and histopathologic classifications: clinical implications

9 October 2023

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Deferral of initial therapy for advanced indolent lymphomas

9 October 2023

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report

9 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy

9 October 2023

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases

9 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas

9 October 2023

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Advanced diffuse histiocytic lymphoma, a potentially curable disease

9 October 2023

23

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

9 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group)

9 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy

9 October 2023

26

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

9 October 2023

27

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables

9 October 2023

28

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma

9 October 2023

29

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Combination Chemotherapy of Advanced Diffuse Histiocytic Lymphoma with the Six-Drug COP-BLAM Regimen

9 October 2023

30

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

The influence of histologic type on the incidence and duration of response in non-Hodgkin's lymphoma

9 October 2023

31

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

9 October 2023

32

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

9 October 2023

33

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

9 October 2023

34

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

VP-16-213 (etoposide): the mandrake root from Issyk-Kul

9 October 2023

35

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience

9 October 2023

36

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia

9 October 2023

37

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

9 October 2023

38

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates

9 October 2023

40

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma

9 October 2023

41

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804

9 October 2023

42

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26)

9 October 2023

47

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas

9 October 2023

48

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

9 October 2023

53

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma

9 October 2023

54

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

9 October 2023

56

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Spontaneous regression in non-Hodgkin's lymphoma

9 October 2023

57

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Role of adenosine deaminase in the early stages of precursor T cell maturation

9 October 2023

58

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

CVP—Remission—maintenance in stage I or II non-Hodgkin's lymphomasPreliminary results of a randomized study

9 October 2023

62

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma

9 October 2023

64

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-hodgkin's lymphoma

9 October 2023

65

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Chemotherapy of localised histiocytic lymphoma

9 October 2023

66

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas

9 October 2023

68

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Gastrointestinal involvement in non-Hodgkin's lymphoma

9 October 2023

69

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Lymphoblastic lymphoma: a clinicopathologic study of 95 patients

9 October 2023

70

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

9 October 2023

Mycosis fungoides

75

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody

9 October 2023

76

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

Cutaneous T cell lymphoma

9 October 2023

77

1 reference

https://api.crossref.org/works/10.1016/0277-5379(84)90074-9

9 October 2023

Identifiers

1 reference

18 September 2017

1 reference